Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09GYT
|
|||
| Former ID |
DAP000796
|
|||
| Drug Name |
Methoxamine
|
|||
| Synonyms |
Methoxamedrin; Methoxamedrine; Methoxamin; Methoxaminum; Metossamina; Metoxamina; Pseudomethoxamine; Vasoxin; Vasoxine; Metossamina [DCIT]; Methoxamine (BAN); Methoxamine [INN:BAN]; Methoxaminum [INN-Latin]; Metoxamina [INN-Spanish]; AQ-387/40213491; Alpha-(1-Aminoethyl)-2,5-dimethoxybenzyl alcohol; DL-2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-Amino-1-(2,5-dimethoxyphenyl)-1-propanol; 2-Amino-1-(2,5-dimethoxyphenyl)propanol; 2-amino-1-(2,5-dimethoxyphenyl)propan-1-ol; 2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1], [2] | |
| Therapeutic Class |
Antihypertensive Agents
|
|||
| Company |
Glaxosmithkline
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H17NO3
|
|||
| Canonical SMILES |
CC(C(C1=C(C=CC(=C1)OC)OC)O)N
|
|||
| InChI |
1S/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3
|
|||
| InChIKey |
WJAJPNHVVFWKKL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 390-28-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9716, 3249415, 7640130, 8153800, 10521352, 11363915, 11366477, 11369039, 11371595, 11373680, 11377201, 11466563, 11467683, 11484588, 11486206, 11488592, 11490314, 11491866, 11494835, 14822464, 29225091, 46506264, 47275534, 47275535, 47424221, 47943743, 48018885, 48094523, 48243341, 48416249, 49698962, 49892579, 50105260, 50941559, 53790926, 57323173, 85209476, 90341132, 95511867, 96024891, 103174599, 103936361, 104311067, 124749985, 124880762, 124880763, 125823506, 126688480, 129588714, 134338081
|
|||
| ChEBI ID |
CHEBI:6839
|
|||
| SuperDrug ATC ID |
C01CA10
|
|||
| SuperDrug CAS ID |
cas=000390283
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor alpha-1B (ADRA1B) | Target Info | Stimulator | [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Vascular smooth muscle contraction | ||||
| Salivary secretion | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Alpha adrenergic receptor signaling pathway | |||
| Pathway Interaction Database | LPA receptor mediated events | |||
| Reactome | Adrenoceptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| AMPK Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 483). | |||
| REF 2 | Drug information of Methoxamine, 2008. eduDrugs. | |||
| REF 3 | Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.